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stem-like cells (CSLCs) 2-4
CSLCs
pancreatic CSLCs P-CSLCs CD24 CD44 epithelial-specific antigen (ESA)
5 CD133 6 aldehyde dehydrogenase 1 
(ALDH1) 7 c-Met 8 doublecortin-like kinase 1 (DCLK1) 9 P-CSLCs
CSLCs CD44 variant isoform CD44v9
CD44v9 reactive oxygen species 
(ROS) 10
P-CSLCs 11
CD24 CD44 ESA CD44v9
P-CSLCs











YPK2 YPK516 (Life Technologies, 
Tokyo, Japan) 10% DMEM-F12  (Sigma-Aldrich Japan, Tokyo, Japan) 37 °C 5% 
CO2
4-2 P-CSLCs
LIF (Merck Millipore, Darmstadt, Germany) NSF-1 (Lonza, Tokyo, Japan) N-acetyl-L-cysteine 
(NAC; Sigma-Aldrich) 1 sphere
sphere B27 supplement (Life Technologies) EGF 





Dead Cell Removal MicroBeads (Miltenyi Biotec, Gladbach, Germany) MidiMACS™ 
Separator (Miltenyi Biotec) CD44v9 rat IgG (clone RV3, Cosmo bio, Tokyo, Japan)
anti-rat mouse IgG (eBioscience, San Diego, CA, USA) microbeads anti-biotin mouse 
IgG (Miltenyi Biotec) MidiMACS™ Separator CD44v9
YPK YPK-Lm CD44v9 0.2% pharmalyte
5M Urea, 2M Thiourea, 2% CHAPS, 2% SB3-10, 1% DTT
0.34ml 18 cm Immobiline Drystrip(pH 3–10, GE Healthcare, 
Tokyo, Japan) Immobiline Drystrip Multiphor II 
6 
Electrophoresis Unit CoolPhoreStar IPG-IEF Type-P (Anatech, Tokyo, Japan)
500 V 1 3,500 V 7.5 A 50 mM Tris-HCl 
(pH 6.8), 6 M urea, 32% glycerol, 10% SDS, 0.25% DTT B 50 mM Tris-HCl 
(pH 6.8), 6 M urea, 32% glycerol, 10% SDS, 4.5% , 0.125% 
Immobiline Drystrip  (9–18% acrylamide; Towa 
Environment Science, Osaka, Japan) ANDERSON ISO-DALT Multiple Electrophoresis System 
(Hoefer, Holliston, MA, USA) 80 V 16 SDS
SYPRO Ruby protein gel stain (S21900; 
Thermo Fisher Scientific, Waltham, MA, USA) Molecular Imager FX 




50 mM 5 mM 0.01 g/ l
37 16 5% TFA 5%TFA 50%
20 3 10 l
ZipTip C18 pipette tips (ZTC18S960, Merck Millipore)
50% 0.1%TFA 1 l
(0.3 g/l alpha-cyano-4-hydroxycinnamic acid, 33% acetone, 66% ethanol target plate 
(MTP Anchorchip 600/384, Bruker Daltonics, Bremen, Germany)  (Ultraflex 
TOF/TOF; Bruker Daltonics) MS/MS NCBInr
Mascot database search engine (Matrix Science, London, UK) 
4-5
YPK2-Lm YPK5-Lm CRT CD44v9 CD47
7 
50ml 2% PBS
2 × 105 cells/100 l
1
1 isotype 20 4
1
rat anti-CD44v9 (clone RV3, Cosmo bio, Tokyo, Japan)  
mouse Alexa Fluor 488 anti-CRT (clone #326203, R&D systems, Minneapolis, MN, USA)  
Vioblue  anti-CD47 (#130-101-359, Miltenyi Biotec, Gladbach, Germany)  
CD44v9 2 allophycocyanin donkey anti-rat IgG (eBioscience)
2 CRT
CD44v9 Fix/Permeabilization buffer (eBioscience) 20
 PBS permeabilization buffer (eBioscience) 10
Blocking buffer (2% normal rat serum in permeabilization buffer)
Alexa Fluor 488  anti-CRT  (clone 326203, R&D systems) 
isotype control 20 Permeabilization buffer 2% FBS
PBS MACSQuant analyzer (Miltenyi Biotec) 
Relative fluorescence intensity (RFI)  
= [mean fluorescence intensity (MFI) - MFI of corresponding isotype control]/MFI of corresponding 
isotype control17
4-6
YPK-Lm CRT, CD44v9 BD FACSAriaII (BD Biosciences, San Jose, CA, 





side population (SP) ABC Hoechst 33342
19 ABC YPK2-Lm YPL5-Lm
5% FBS DMEM 5 g/ml Hoechst 33342 (Sigma-Aldrich Japan) 30 min
BD LSRFortessa X-20 cell analyzer (BD Biosciences)
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10 mM Target Retrieval Solution, pH 
6.0 (Dako, Tokyo, Japan) 
CRT 3% H2O2 10 CD44v9 0.3% H2O2
5 Protein block serum-free (Dako)
1 2
1 mouse anti-CRT monoclonal antibody (clone FMC75, Abcam, 
Cambridge, MA, USA): 1:6000 1
2 House raddish peroxidase (HRP) anti-mouse IgG Dako
9 
30
1 rat anti- CD44v9 monoclonal antibody (clone RV3, Cosmo bio) 
1:200,4 °C, overnight 
    2 HRP  anti-rat IgG  (Nichirei Biosciences, Tokyo, Japan). 
PBS 3,3 -diaminobenzidine tetrahydrochloride (DAB; Dako) 3
21
a) absent / weak :1 b) moderate: 2 c) strong: 3
IHC × % (=1×absent / weak % 2×moderate %
3×strong % ) 
(3)
   citrate buffer (10 mM, pH 6.0) 95 °C 10 5% 0.3% Triton X-
100 PBS 60 CRT CD44v9
Anti-CRT antibody (FMC75, Abcam) 1:200
1 Alexa Fluor 488 anti-mouse IgG (#4408, Cell Signaling Technology, Denver, MA, USA) 
1:1,000 1.5 anti-CD44v9 rat antibody (RV3, Cosmo bio) 1:100 1
Alexa Fluor 555  anti-rat IgG (#4417, Cell Signaling Technology) 1:1,000 1.5
DAPI ProLong Gold Antifade Reagent (#8961; Cell Signaling Technology)
4-9
 ± Student’s t-test Chi-squared
Kaplan-Meier Wilcoxon test




YPK2-Lm 4.43 YPK5-Lm 5.80
(Fig. 1A–D, ) Calreticulin (CRT) (NCBI accession No. gi|4757900) (Fig. 1E)
5-2. YPK-Lm CRT CD44v9
YPK2-Lm YPK5-Lm
CRT CD44v9  (Fig. 2A, B) YPK-Lm CRThigh/CD44v9low
CRTlow/CD44v9high 2 (Fig. 2C, D) CRT YPK-Lm
 (Fig. 2E, F)
5-3.YPK-Lm CD47
CD47 CRT  ”eat me signal”  “anti-phagocytic signal” 22
CD47 YPK-Lm
Fig. 3A 22 CRT CD47
Fig. 3B
5-4. YPK-Lm ABC
YPK2 side population ( SP) 0.338% YPK2- Lm
34.0%  (Fig. 2G) YPK5-Lm SP 12.9%
SP(1.72%)  (Fig. 2H) YPK- Lm CRThigh/CD44v9low SP







Fig. 5 1/3  (n = 26) 
(n = 67) CRT Fig. 6A
CRT
CD44v9 Fig. 6B CD44v9
CRT CD44v9
IHC ( : 0.356 [0.148–0.534], p = 0.0012) 
Cox
23-25 TNM T CRT
CD44v9 IHC CRT
IHC (p < 0.01)  (p < 0.01)  (p < 0.05) 
 (Table 1)
1 CRT IHC 150 CRT
 (IHC score   150; n = 43) CRT  (IHC score < 150; n = 37) 
CD44v9  (IHC score   165; n = 40) CD44v9  (IHC score < 165; n = 40) 
CRT Table 2 CRT
T3 Stage II CD44v9
CRT  (p = 














CRT ”unfolded protein response”
26





SP CSLCs 28 SP
13 
29 CRThigh/CD44v9low






CRT “eat-me” signal 13
CRT 30 31 15
2 22 1 CRT anti-phagocytic 
signal CD47 CRT CD47
CD47 YPK-Lm
P-CSLCs CD47 2 CRT
CRT neuropilin-1, matrix 
metalloproteinase (MMP)2, MMP9, focal adhesion kinase (FAK) upregulate
32 phosphoinositide 3-kinase (PI3K)/Akt pathway 
anoikis
33 CRT
CRT LDL-receptor related protein 1 
(LRP1)/CD91 34
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Fig. 1. Calreticulin
A-D: YPK2 A, C YPK2-Lm B, D 2
E: MALDI TOF/TOF MS calreticulin
18 
Fig. 2. 
A, B: (A)YPK2 YPK2-Lm (B) YPK5 YPK5-Lm CRT
CD44v9
C, D: (C)YPK2 YPK2-Lm (D) YPK5 YPK5-Lm
19 
CRT CD4v9
E, F: (E)YPK2 YPK2-Lm F (E)YPK5 YPK5-Lm
CRT
G,H: (G)YPK2 YPK2-Lm H (E)YPK5 YPK5-Lm
Hoechst33342
Fig.3. CD47
A: YPK YPK-Lm CD47
B: CRT CD47  -0.1585 (95% confidence interval: -0.6356 – 0.4063) p > 0.05 
20 
Fig. 4. YPK-Lm sort Side population (SP) 
(A) YPK2-Lm calreticulin (CRT)high/CD44 variant isoform 9 (CD44v9)low ( )  CRTlow/CD44v9high
( ) CRThigh/CD44v9high ( ) 3 sort ATP-binding cassette transporter
(B) CRThigh/CD44v9low SP 88.5% (C) CRTlow/CD44v9high SP 2.42%
21 
(D) CRThigh/CD44v9high SP 3.32% (E) YPK5-Lm CRThigh/CD44v9low
( )  CRTlow/CD44v9high ( ) CRThigh/CD44v9high ( ) sort ATP-binding cassette transporter
(F) CRThigh/CD44v9low SP 43.1% (G) CRTlow/CD44v9high SP
0.78% (H) CRThigh/CD44v9high SP 12.4%
Fig.5. 
IHC; immunohistochemistry, 





Fig.6: Calreticulin (CRT) CD44v9
islet
acinusduct


















C: CRT CD44v9 50 m 
Table 1. Cox
Variable     SE p-value  Hazard ratio (95% CI) 
Age    0.051 0.017 0.002  1.053 (1.019-1.088) 
CRT IHC score   0.007 0.002 0.004  1.007 (1.002-1.011) 
Post-operative therapy  -0.815 0.365 0.026  0.443 (0.216-0.905) 
CRT, calreticulin; IHC, immunohistochemistry; SE, standard error; 95% CI, 95% confidence interval. 
24 
Table 2. CRT
Variable     CRT expression    P-value 
    Low (n = 37)  High (n = 43) 
Age, years.  
mean ± SD   68.1 ± 7.6   65.6 ± 9.5   0.199 
Gender, No.  
Male   17   18   0.713 
Female   20   25     
Tumor location, No.  
Head   24   31   0.487 
Body – tail   13   12    
Tumor size, mm 
 mean ± SD   25.7 ± 9.9   29.8 ± 17.8   0.356 
Differentiation, No. 
 Well   1   5   0.139 
 Moderate – poor  36   38     
Invasion depth, No. 
 T1   5   2   0.013
 T2   5   0 
 T3   27   41 
Lymph node metastasis, No. 
 Negative   21   20   0.361 
 Positive   16   23    
TNM stage, No. 
 I   7   2   0.048
 II   30   41 
Perineural invasion 
 Negative   9   3   0.030
 Positive   28   40 
Portal invasion 
 Negative   24   26   0.685 
 Positive   13   17 
Pre-operative therapy, No. 
 None   20   34   0.017
 Performed   17   9 
Post-operative therapy, No. 
 None   5   8   0.538 
25 
 Performed   32   35    
CD44v9 expression, No. 
 Low   25   15   0.004
 High   12   28 
26 
Fig.7. CRT CRT
